Key Highlights
- Forge Nano (NASDAQ:NANO) fell 16.59% on November 16, 2026 after reporting third-quarter results and reiterating its 2026 outlook in its first update since listing on October 22.
- The company raised more than USD 130 million in gross proceeds through its listing, including a USD 123 million private placement.
- TRexBio, another October debut, fell 21.21% after reporting a third-quarter net loss of USD 13.2 million, up from USD 7.9 million a year earlier.
- Both moves came in a session when the Nasdaq Composite lost 2.49% and investors sold recently listed, loss-making growth stocks.
Forge Nano's First Public Report
Forge Nano (NASDAQ:NANO) supplies atomic layer deposition technology, a method of applying coatings a few atoms thick, used in semiconductor equipment and battery materials. It began trading on Nasdaq on October 22, 2026 after combining with a special purpose Acquisition company, and its November 16 report was the first quarterly update as a listed business. The company said it raised more than USD 130 million in gross proceeds, made up of a USD 123 million private Placement and about USD 8.4 million left in the trust after redemptions, before transaction costs. It completed the all-stock acquisition of HZO, a protective-coatings business, on November 4 and signed a joint development agreement in September to Supply equipment for a pharmaceutical drug-coating platform. Management reiterated its 2026 outlook of about USD 18 million of revenue, USD 12.7 million of government grant income and USD 9.4 million of HZO Revenue on a full-year basis. That combined figure is well below the roughly USD 40 million target set in April 2026, a gap that likely weighed on sentiment because investors had anchored to the earlier number when the listing was marketed.
TRexBio Joins the Sell-Off
TRexBio, which priced its initial public offering in October at USD 14.00 per share, fell 21.21%, the steepest decline among notable movers on the day. The immunology company sold 9,539,237 shares, raising about USD 133.5 million gross and USD 119.0 million net. Its third-quarter report, released after the close on November 13, showed a net loss of USD 13.2 million, compared with USD 7.9 million a year earlier, as Research and Development spending rose to USD 11.4 million from USD 7.0 million. Cash and marketable securities stood at USD 78.2 million on September 30, excluding the IPO proceeds, and the company said its resources fund operations into the second half of 2029. Its lead candidate, a TNFR2 agonist designed to activate regulatory T cells, produced positive early safety data and is now in a mid-stage atopic dermatitis study with topline results expected in mid-2027. Nothing in the report was alarming, which suggests the decline reflected selling by IPO buyers as much as the numbers themselves.
What the Moves Say About Recent Listings
Both stocks share features that left them exposed: limited trading history, few established holders and no profits. When the broad market turns, as it did on November 16 when the S&P 500 dropped 1.92% and Volatility jumped, these names often fall harder because early investors take gains or cut losses. For Forge Nano (NASDAQ:NANO), the Investment case rests on longer-term projects, including a battery-materials factory in North Carolina planned to start production in 2028 and supported by a federal cost-share grant of up to USD 100 million. Those projects require Capital and execution, and the stock will likely track progress on orders, grant disbursements and Margin improvement. TRexBio's path is tied to clinical milestones, with its second candidate expected to enter a Phase 1 trial in the first half of 2027. Lock-up expirations, typically about six months after listing, are another overhang for both companies to monitor.
Where Things Stand
Forge Nano and TRexBio, two October market debuts, fell sharply after their first public results in a broad risk-off session. Forge Nano reiterated a 2026 outlook well below earlier targets, while TRexBio reported a wider loss but a cash runway into the second half of 2029. Order momentum at Forge Nano and clinical progress at TRexBio will determine whether the declines persist.






Please wait processing your request...